Cargando…

Exploring adverse drug events at the class level

BACKGROUND: While the association between a drug and an adverse event (ADE) is generally detected at the level of individual drugs, ADEs are often discussed at the class level, i.e., at the level of pharmacologic classes (e.g., in drug labels). We propose two approaches, one visual and one computati...

Descripción completa

Detalles Bibliográficos
Autores principales: Winnenburg, Rainer, Sorbello, Alfred, Bodenreider, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416343/
https://www.ncbi.nlm.nih.gov/pubmed/25937884
http://dx.doi.org/10.1186/s13326-015-0017-1
_version_ 1782369222523879424
author Winnenburg, Rainer
Sorbello, Alfred
Bodenreider, Olivier
author_facet Winnenburg, Rainer
Sorbello, Alfred
Bodenreider, Olivier
author_sort Winnenburg, Rainer
collection PubMed
description BACKGROUND: While the association between a drug and an adverse event (ADE) is generally detected at the level of individual drugs, ADEs are often discussed at the class level, i.e., at the level of pharmacologic classes (e.g., in drug labels). We propose two approaches, one visual and one computational, to exploring the contribution of individual drugs to the class signal. METHODS: Having established a dataset of ADEs from MEDLINE, we aggregate drugs into ATC classes and ADEs into high-level MeSH terms. We compute statistical associations between drugs and ADEs at the drug level and at the class level. Finally, we visualize the signals at increasing levels of resolution using heat maps. We also automate the exploration of drug-ADE associations at the class level using clustering techniques. RESULTS: Using our visual approach, we were able to uncover known associations, e.g., between fluoroquinolones and tendon injuries, and between statins and rhabdomyolysis. Using our computational approach, we systematically analyzed 488 associations between a drug class and an ADE. CONCLUSIONS: The findings gained from our exploratory techniques should be of interest to the curators of ADE repositories and drug safety professionals. Our approach can be applied to different drug-ADE datasets, using different drug classification systems and different signal detection algorithms. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13326-015-0017-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4416343
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44163432015-05-02 Exploring adverse drug events at the class level Winnenburg, Rainer Sorbello, Alfred Bodenreider, Olivier J Biomed Semantics Research Article BACKGROUND: While the association between a drug and an adverse event (ADE) is generally detected at the level of individual drugs, ADEs are often discussed at the class level, i.e., at the level of pharmacologic classes (e.g., in drug labels). We propose two approaches, one visual and one computational, to exploring the contribution of individual drugs to the class signal. METHODS: Having established a dataset of ADEs from MEDLINE, we aggregate drugs into ATC classes and ADEs into high-level MeSH terms. We compute statistical associations between drugs and ADEs at the drug level and at the class level. Finally, we visualize the signals at increasing levels of resolution using heat maps. We also automate the exploration of drug-ADE associations at the class level using clustering techniques. RESULTS: Using our visual approach, we were able to uncover known associations, e.g., between fluoroquinolones and tendon injuries, and between statins and rhabdomyolysis. Using our computational approach, we systematically analyzed 488 associations between a drug class and an ADE. CONCLUSIONS: The findings gained from our exploratory techniques should be of interest to the curators of ADE repositories and drug safety professionals. Our approach can be applied to different drug-ADE datasets, using different drug classification systems and different signal detection algorithms. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13326-015-0017-1) contains supplementary material, which is available to authorized users. BioMed Central 2015-05-01 /pmc/articles/PMC4416343/ /pubmed/25937884 http://dx.doi.org/10.1186/s13326-015-0017-1 Text en © Winnenburg et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Winnenburg, Rainer
Sorbello, Alfred
Bodenreider, Olivier
Exploring adverse drug events at the class level
title Exploring adverse drug events at the class level
title_full Exploring adverse drug events at the class level
title_fullStr Exploring adverse drug events at the class level
title_full_unstemmed Exploring adverse drug events at the class level
title_short Exploring adverse drug events at the class level
title_sort exploring adverse drug events at the class level
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416343/
https://www.ncbi.nlm.nih.gov/pubmed/25937884
http://dx.doi.org/10.1186/s13326-015-0017-1
work_keys_str_mv AT winnenburgrainer exploringadversedrugeventsattheclasslevel
AT sorbelloalfred exploringadversedrugeventsattheclasslevel
AT bodenreiderolivier exploringadversedrugeventsattheclasslevel